Modular bacteriophage t4 nanoparticle platform enables rapid design of dual covid-19-flu mucosal vaccines
AssigneeThe Catholic University of America
InventorsVenigalla B. Rao, Jingen Zhu
Life of this patent
Estimating the term…
Abstract
A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.
Claims38
A bacteriophage nanoparticle vaccine composition, comprising:
- a bacteriophage capsid and
- at least one antigen displayed on a surface of the capsid or packaged in its interior,
- wherein the vaccine is administered intranasally and is free of an adjuvant.
A method of producing a bacteriophage nanoparticle vaccine, comprising:
- engineering a bacteriophage nanoparticle to display an antigen;
- expressing and purifying the antigen;
- attaching the antigen to the nanoparticle;
- and
- formulating the resulting nanoparticle in a pharmaceutically acceptable buffer for an administration.
A method of inducing an immune response against at least one virus in a subject, comprising:
- administering intranasally to a subject an effective amount of a bacteriophage nanoparticle vaccine.
A multivalent mucosal vaccine composition comprising a bacteriophage T4 nanoparticle,
- wherein the nanoparticle comprises:
- one or more capsid surface antigens selected from the group comprising SARS-COV-2 spike ectodomain trimers, influenza hemagglutinin stem trimers, or influenza M2e peptides;
- one or more internal antigens encapsulated within the capsid, selected from the group comprising SARS-COV-2 nucleocapsid protein or influenza matrix protein 1;
- and
- a SpyCatcher-SpyTag conjugation system configured to covalently attach said spike or hemagglutinin trimers to the capsid surface;
- wherein the nanoparticle is non-infectious, adjuvant-free, and configured for intranasal administration to induce mucosal and systemic immunity against both SARS-CoV-2 and influenza.
A modular vaccine platform comprising a bacteriophage T4 nanoparticle engineered to:
- display one or more heterologous antigens on a capsid exterior surface via a Hoc or Soc fusion protein, and encapsulate one or more heterologous antigens within a capsid interior via a capsid-targeting sequence (CTS), wherein the nanoparticle is non-infectious, adjuvant-free, and formulated for mucosal administration to induce local and systemic immune responses.
Dependencies are inferred from the claim text.